Paratek Pharmaceuticals Announced Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Top Line Data From Pilot Efficacy Study For The Treatment Of Pulmonary Anthrax And Acceptance Of The Second Procurement Of NUZYRA Under BARDA Project BioShield
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100%
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Paratek Announces First Milestone Towards Creating A U.S. Manufacturing Supply Chain For NUZYRA Under BARDA Project BioShield Contract
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and
Earnings Preview For Paratek Pharmaceuticals
Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement.
Analysts estimate that Paratek Pharmaceuticals will report an earnings per share (EPS) of $-0.34.
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap of Tuesday’s Biotech Catalysts – End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Ionis shares are trading low 4 percent at $35.10 in the after-hours session